ESR1 and breast carcinoma: ERα+ breast cancers are treated with targeted inhibitors that block ERα signaling, including selective ERα modulators (SERMS, e.g., tamoxifen), selective ERα downregulators (SERDs, e.g., fulvestrant) and AIs that decrease circulating estrogen in post-menopausal women.